Active replication — ongoing trial, registry, or meta-analysis.
Recent follow-up analyses of EMERGE (aducanumab) are confirming the original effect size in real-world data.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0656
Recent follow-up analyses of CLARITY-AD (lecanemab) are confirming the original effect size in real-world data.
0.0821
The EMERGE (aducanumab) trial's stated primary conclusion — Aducanumab’s pivotal phase 3 showed mixed evidence for cognitive slowing in early Alzheimer disease. — replicates in independent cohorts.
0.1373
Recent follow-up analyses of EMILIA are confirming the original effect size in real-world data.
0.1437
Recent follow-up analyses of EXTEND-IA are confirming the original effect size in real-world data.
0.1449
Recent follow-up analyses of MEMBRANE are confirming the original effect size in real-world data.
0.1460
Recent follow-up analyses of EMPEROR-Reduced are confirming the original effect size in real-world data.